29
Apr

Amgen took its best case for its dual cancer-killing oncolytic virus/cancer vaccine talimogene laherparepvec (T-Vec) to an FDA advisory committee this morning.

…read more

Source: Amgen faces a critical review for T-Vec

    

0 No comments